TABLE 1.

In vitro inhibition of influenza A (H5N1) virus replication by T-705, oseltamivir carboxylate, zanamivir, and ribavirina

VirusMeanb neutral red EC50 (μM) ± SDVirus yield reduction EC90 (μM) ± SD
T-705Oseltamivir carboxylateZanamivirRibavirinT-705Oseltamivir carboxylateZanamivirRibavirin
A/Hong Kong/213/03 × Ann Arbor/6/602.6 ± 1.30.032 ± 0.0180.09 ± 0.0914.3 ± 5.31.3 ± 0.60.07 ± 0.040.42 ± 0.3333.2 ± 22.5
A/Vietnam/1203/04 × Ann Arbor/6/6012.1 ± 17.30.0014 ± 0.00070.012 ± 0.01535.7 ± 15.23.8 ± 0.60.007 ± 0.0070.09 ± 0.0618.4 ± 9.4
A/Duck/MN/1525/814.5 ± 3.80.14 ± 0.210.15 ± 0.0643.0 ± 18.42.6 ± 0.60.92 ± 1.30.96 ± 1.3220.1 ± 12.3
A/Gull/PA/4175/8311.5 ± 10.90.28 ± 0.070.15 ± 0.0938.1 ± 2.57.7 ± 4.20.67 ± 0.211.23 ± 2.0732.0 ± 26.2
  • a The CC50s for each compound were as follows: T-705, >641 μM; oseltamivir carboxylate, >3,521 μM; zanamivir, >3,612 μM; ribavirin, 2,336 ± 943 μM.

  • b Results of two to five experiments with each compound.